Therapy duration and long-term outcomes in extra-pulmonary tuberculosis

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Pusch, Tobias ^a   Pasipanodya, Jotam G ^a   Hall II, Ronald G ^b   Gumbo, Tawanda ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Extra pulmonary tuberculosis; Meningitis; Peritoneal; Survival; Therapy duration

Indexed keywords

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT TUBERCULOSIS; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT DURATION; TUBERCULOUS ARTHRITIS; TUBERCULOUS MENINGITIS; TUBERCULOUS OSTEOMYELITIS; TUBERCULOUS PERITONITIS; UNITED STATES; UROGENITAL TUBERCULOSIS; COMPLICATION; INCIDENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TEXAS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84895423216     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-115     Document Type: Article

References (54)

1. World Health Organization Tuberculosis factsheet No 104 2011, Geneva, Switzerland: World Health Organization, World Health Organization.
2. World Health Organization TB Epidemiology and Surveillance Workshop. (Increasing/Decreasing Over/Under/Diagnosis of Extrapulmonary TB) 2005, Geneva, Switzerland, World Health Organization.
3. Zhang X, Andersen AB, Lillebaek T, Kamper-Jorgensen Z, Thomsen VO, Ladefoged K, Marrs CF, Zhang L, Yang Z. Effect of sex, age, and race on the clinical presentation of tuberculosis: a 15-year population-based study. Am J Trop Med Hyg 2011, 85:285-290. 10.4269/ajtmh.2011.10-0630, 3144827, 21813849.
4. Nacci F, Matucci-Cerinic M. Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF-alpha) era. Best Pract Res Clin Rheumatol 2011, 25:375-388. 10.1016/j.berh.2011.06.001, 22100287.
5. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003, 167:603-662.
6. Shaw JE, Pasipanodya JG, Gumbo T. Meningeal tuberculosis: high long-term mortality despite standard therapy. Medicine (Baltimore) 2010, 89:189-195. 10.1097/MD.0b013e3181df9070, 20453606.
7. Thwaites GE, Simmons CP, Than Ha QN, Thi Hong CT, Phuong MP, Thi DN, Hoan PN, White NP, Tinh HT, Farrar JJ. Pathophysiology and prognosis in Vietnamese adults with tuberculous meningitis. J Infect Dis 2003, 188:1105-1115. 10.1086/378642, 14551879.
8. Thwaites GE, Bhavnani SM, Chau TT, Hammel JP, Torok ME, Van Wart SA, Mai PP, Reynolds DK, Caws M, Dung NT, Hien TT, Kulawy R, Farrar J, Ambrose PG. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother 2011, 55:3244-3253. 10.1128/AAC.00064-11, 3122453, 21502621.
9. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, Nguyen QH, Nguyen TT, Nguyen NH, Nguyen TN, Nguyen NL, Nguyen HD, Vu NT, Cao HH, Tran TH, Pham PM, Nguyen TD, Stepniewska K, White NJ, Tran TH, Farrar JJ. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004, 351:1741-1751. 10.1056/NEJMoa040573, 15496623.
10. Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven AJ, Borm G, Aarnoutse RE, Van CR. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013, 13:27-35. 10.1016/S1473-3099(12)70264-5, 23103177.
11. Dutt AK, Moers D, Stead WW. Short-course chemotherapy for extrapulmonary tuberculosis: nine years' experience. Ann Intern Med 1986, 104:7. 10.7326/0003-4819-104-1-7, 3940507.
12. Kwara A, Roahen-Harrison S, Prystowsky E, Kissinger P, Adams R, Mathison J, Hyslop NE. Manifestations and outcome of extra-pulmonary tuberculosis: impact of human immunodeficiency virus co-infection. Int J Tuberc Lung Dis 2005, 9(5):485-493.
13. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, Drewyer G, Weis SE. Pulmonary impairment after tuberculosis. Chest 2007, 131:1817-1824. 10.1378/chest.06-2949, 17400690.
14. Pasipanodya JG, McNabb SJ, Hilsenrath P, Bae S, Lykens K, Vecino E, Munguia G, Miller TL, Drewyer G, Weis SE. Pulmonary impairment after tuberculosis and its contribution to TB burden. BMC Public Health 2010, 10:259. 10.1186/1471-2458-10-259, 2894771, 20482835.
15. Arias E. United States life tables, 2004. National vital statistics reports 2007, Hyattsville, MD: National Center for Health Statistics, Volume 56, 9.
16. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B. Paediatric tuberculosis. Lancet Infect Dis 2008, 8:498-510. 10.1016/S1473-3099(08)70182-8, 2804291, 18652996.
17. Horsburgh CR, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, Hughes S, Shrestha-Kuwahara R, Sterling TR, Wall K, Weinfurter P. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010, 137:401-409. 10.1378/chest.09-0394, 19793865.
18. Hermansen SW, Leitzmann MF, Schatzkin A. The impact on national death index ascertainment of limiting submissions to social security administration death master file matches in epidemiologic studies of mortality. Am J Epidemiol 2009, 169:901-908. 10.1093/aje/kwn404, 2732974, 19251755.
19. Park Y, Hartge P, Moore SC, Kitahara CM, Hollenbeck AR, De Berrington GA. Body mass index and mortality in non-Hispanic black adults in the NIH-AARP diet and health study. PLoS ONE 2012, 7:e50091. 10.1371/journal.pone.0050091, 3507927, 23209650.
20. Sesso HD, Paffenbarger RS, Lee IM. Comparison of national death index and world wide web death searches. Am J Epidemiol 2000, 152:107-111. 10.1093/aje/152.2.107, 10909946.
21. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013, 208:1464-1473. 10.1093/infdis/jit352, 23901086.
22. Lewis RJ. An introduction to classification and regression tree (CART) analysis. 2000 Annual Meeting of the Society for Academic Emergency Medicine 2000, Des Plaines, IL: Society for Academic Emergency Medicine.
23. Steinberg D, Colla P. CART: Tree-Structured Non-parametric Data Analysis 1995, San Diego: Salford Systems.
24. Breiman L, Friedman J, Stone CJ, Olshen RA. Classification and Regression Trees 1984, Boca Raton: Chapman and Hall/CRC.
25. Breiman L. Prediction games and arcing algorithms. Neural Comput 1999, 11:1493-1517. 10.1162/089976699300016106, 10490934.
26. Breiman L. Technical note: some properties of splitting criteria. Mach Learn 1996, 24:41-47.
27. Jain MK, Pasipanodya JG, Alder L, Lee WM, Gumbo T. Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. Antimicrob Agents Chemother 2013, 57:1115-1120. 10.1128/AAC.02208-12, 3591896, 23183434.
28. Osler W. The Principles and Practice of Medicine 1892, New York: Appleton, 1.
29. Canetti G. The tubercle bacillus in the pulmonary lesion of man 1955, New York: Springer Publishing Company.
30. Koch R. Die atiologie der tuberkulose. Berliner Klinischen Wocheschrift 1882, 15:221-230.
31. Canetti G, Grumbach F, Grosset J. Studies of bacillary populations in experimental tuberculosis of mice treated by isoniazid. Am Rev Respir Dis 1960, 82:295-313.
32. McCune RM, Feldmann FM, Lambert HP, McDermott W. Microbial persistence: I: the capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 1966, 123:445-468. 10.1084/jem.123.3.445, 2138153, 4957010.
33. Tompsett R, McCune RM, Ormond L, Deuschle K, Muschenheim C, McDermott W. The influence of pyrazinamide-isoniazid on M. tuberculosis in animals and man. Trans Assoc Am Physicians 1954, 67:224-231.
34. Mitchison DA. Basic mechanisms of chemotherapy. Chest 1979, 76:771-781. 10.1378/chest.76.6_Supplement.771, 92392.
35. Garton NJ, Waddell SJ, Sherratt AL, Lee SM, Smith RJ, Senner C, Hinds J, Rajakumar K, Adegbola RA, Besra GS, Butcher PD, Barer MR. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 2008, 5:e75. 10.1371/journal.pmed.0050075, 2276522, 18384229.
36. Eum SY, Kong JH, Hong MS, Lee YJ, Kim JH, Hwang SH, Cho SN, Via LE, Barry CE. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 2010, 137:122-128. 10.1378/chest.09-0903, 2803122, 19749004.
37. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS ONE 2011, 6:e17601. 10.1371/journal.pone.0017601, 3070694, 21483732.
38. Katrak SM, Shembalkar PK, Bijwe SR, Bhandarkar LD. The clinical, radiological and pathological profile of tuberculous meningitis in patients with and without human immunodeficiency virus infection. J Neurol Sci 2000, 181:118-126. 10.1016/S0022-510X(00)00440-8, 11099721.
39. Shukla R, Abbas A, Kumar P, Gupta RK, Jha S, Prasad KN. Evaluation of cerebral infarction in tuberculous meningitis by diffusion weighted imaging. J Infect 2008, 57:298-306. 10.1016/j.jinf.2008.07.012, 18760486.
40. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007, 51:3781-3788. 10.1128/AAC.01533-06, 2151424, 17724157.
41. Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, Drusano GL. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 2007, 51:2329-2336. 10.1128/AAC.00185-07, 1913269, 17438043.
42. Gumbo T, Siyambalapitiyage Dona CS, Meek C, Leff R. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 2009, 53:3197-3204. 10.1128/AAC.01681-08, 2715614, 19451303.
43. Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis 2010, 201:1225-1231. 10.1086/651377, 2838947, 20210628.
44. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012, 55:169-177. 10.1093/cid/cis353, 3491771, 22467670.
45. Jeena PM, Bishai WR, Pasipanodya JG, Gumbo T. In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis. Antimicrob Agents Chemother 2011, 55:539-545. 10.1128/AAC.00763-10, 3028779, 21098246.
46. Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb) 2010, 90:279-292. 10.1016/j.tube.2010.07.002, 20709598.
47. Ge Z, Wang Z, Wei M. Measurement of the concentration of three antituberculosis drugs in the focus of spinal tuberculosis. Eur Spine J 2008, 17:1482-1487. 10.1007/s00586-008-0778-7, 2583188, 18795341.
48. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011, 204:1951-1959. 10.1093/infdis/jir658, 3209814, 22021624.
49. Thwaites G, Caws M, Chau TT, D'Sa A, Lan NT, Huyen MN, Gagneux S, Anh PT, Tho DQ, Torok E, Nhu NT, Duyen NT, Duy PM, Richenberg J, Simmons C, Hien TT, Farrar J. Relationship between Mycobacterium tuberculosis genotype and the clinical phenotype of pulmonary and meningeal tuberculosis. J Clin Microbiol 2008, 46:1363-1368. 10.1128/JCM.02180-07, 2292951, 18287322.
50. Caws M, Thwaites G, Dunstan S, Hawn TR, Lan NT, Thuong NT, Stepniewska K, Huyen MN, Bang ND, Loc TH, Gagneux S, Van SD, Kremer K, Van der SM, Small P, Anh PT, Chinh NT, Quy HT, Duyen NT, Tho DQ, Hieu NT, Torok E, Hien TT, Dung NH, Nhu NT, Duy PM, Van Vinh CN, Farrar J. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog 2008, 4:e1000034. 10.1371/journal.ppat.1000034, 2268004, 18369480.
51. Caws M, Thwaites G, Stepniewska K, Nguyen TN, Nguyen TH, Nguyen TP, Mai NT, Phan MD, Tran HL, Tran TH, Van SD, Kremer K, Nguyen VV, Nguyen TC, Farrar J. Beijing genotype of Mycobacterium tuberculosis is significantly associated with human immunodeficiency virus infection and multidrug resistance in cases of tuberculous meningitis. J Clin Microbiol 2006, 44:3934-3939. 10.1128/JCM.01181-06, 1698365, 16971650.
52. Ford CB, Shah RR, Maeda MK, Gagneux S, Murray MB, Cohen T, Johnston JC, Gardy J, Lipsitch M, Fortune SM. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet 2013, 45:784-790. 10.1038/ng.2656, 3777616, 23749189.
53. Esposito S, Esposito I, Leone S. Considerations of antibiotic therapy duration in community-and hospital-acquired bacterial infections. J Antimicrob Chemother 2012, 67:2570-2575. 10.1093/jac/dks277, 22833640.
54. Breiman L. Random forests. Mach Learn 2001, 45:5-32.